Australian Prescriber Podcast podcast

E139 – SGLT2 inhibitors for kidney and heart disease

0:00
13:39
Recuar 15 segundos
Avançar 15 segundos

Normally used as a glucose-lowering agent in the treatment of type 2 diabetes, SGLT2 inhibitors have been found to have beneficial effects in patients with heart failure and kidney disease. Jo Cheah finds out more from cardiologist John Atherton.

Mais episódios de "Australian Prescriber Podcast"